Briefing
Circulating tumor DNA and late recurrence in high-risk, hormone receptor-positive, HER2-negative breast cancer: An updated analysis of the CHiRP study.
With longer follow-up, all 8/8 patients with ctDNA detected at any timepoint developed distant recurrence (median lead time 1.39 years, range 0.01-4.24). A negative test had a negative predictive value for remaining recurrence-free of 100% at more than 1 year (0/196), 98.4% at more than 2 years (3 events among 185 samples), and 96.6% at more than 3 years (5/147).
- n: same 83-patient analytic cohort as the 2022 abstract; median follow-up from first sample 4.4 years; 214 plasma samples before known recurrence
- Assay: RaDaR (tumor-informed, whole-exome-based)